Get the Stockscreener App
124.12
0.83%
1.02
Neurocrine Biosciences Inc stock is traded at $124.12, with a volume of 2.12M.
It is up +0.83% in the last 24 hours and down -6.15% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$123.10
Open:
$123.83
24h Volume:
2.12M
Relative Volume:
1.94
Market Cap:
$12.46B
Revenue:
$2.68B
Net Income/Loss:
$428.00M
P/E Ratio:
29.64
EPS:
4.1873
Net Cash Flow:
$593.10M
1W Performance:
-12.10%
1M Performance:
-6.15%
6M Performance:
-5.70%
1Y Performance:
+6.20%
1-Day Range:
$123.36
$126.50
1-Week Range:
$122.14
$142.82
52-Week Range:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
124.12 | 12.35B | 2.68B | 428.00M | 593.10M | 4.1873 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Market Rankings: Why is Neurocrine Biosciences Inc. stock going upWeekly Trend Report & Technical Pattern Based Signals - mfd.ru
Can Neurocrine Biosciences Inc. maintain its current growth rateStop Loss & AI Powered Buy and Sell Recommendations - mfd.ru
Why Neurocrine Biosciences Inc. stock remains a top recommendationJuly 2025 Fed Impact & Long-Term Safe Investment Plans - mfd.ru
Neurocrine Biosciences (NBIX) Is Down 12.1% After Issuing 2026 INGREZZA Sales GuidanceWhat's Changed - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Strong 2025 Results And 2026 Guidance - Yahoo Finance
How cyclical is Neurocrine Biosciences Inc.’s revenue streamWeekly Investment Recap & Low Risk Profit Maximizing Plans - mfd.ru
NBIX Rating Maintained, Price Target Lowered by Wells Fargo | NB - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Krilogy Financial LLC Makes New $1.27 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment - ChartMill
Neurocrine Biosciences Enters New Growth Phase With Broader Revenue Mix - simplywall.st
Neurocrine Biosciences: Growth Beyond Just Ingrezza (NASDAQ:NBIX) - Seeking Alpha
Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $204.00 Price Target at Citigroup - MarketBeat
Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance - Benzinga
Neurocrine Biosciences: Expanding Opportunities, 2026 Will Be Less Exciting (NASDAQ:NBIX) - Seeking Alpha
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at Royal Bank Of Canada - MarketBeat
BMO Capital Markets Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says - marketscreener.com
Wedbush Adjusts Neurocrine Biosciences Price Target to $151 From $149, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $151.00 at Wedbush - MarketBeat
Neurocrine Bio. stock price target lowered to $192 at H.C. Wainwright - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Down 9.3% Following Analyst Downgrade - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $192.00 Price Target at HC Wainwright - MarketBeat
Needham & Company LLC Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $185.00 - MarketBeat
RBC Trims Price Target on Neurocrine Biosciences to $177 From $180, Keeps Outperform Rating - marketscreener.com
Neurocrine Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2025 Earnings Call Transcript - Insider Monkey
Forecasting The Future: 10 Analyst Projections For Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Impax Asset Management Group plc - MarketBeat
Is Neurocrine Biosciences (NBIX) Pricing Reflecting Its Strong 1 Year Share Performance? - simplywall.st
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Neurocrine Biosciences (NASDAQ:NBIX) Posts Earnings Results, Misses Estimates By $0.48 EPS - MarketBeat
Neurocrine Biosciences Q4 Earnings Call Highlights - MarketBeat
Neurocrine Q4 2025 slides: INGREZZA, CRENESSITY fuel 22% annual growth - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises - Investing.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot - KVUE
Neurocrine: Fourth Quarter Earnings Overview - Bitget
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance - Investing.com Australia
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance - marketscreener.com
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance By Investing.com - Investing.com South Africa
Neurocrine Biosciences Inc Profit Advances In Q4 - Nasdaq
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe - Stock Titan
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PR Newswire
Neurocrine Biosciences Q4 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENEVICH ERIC | Chief Commercial Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,294 |
0 |
54,047 |
| ABERNETHY MATT | Chief Financial Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,437 |
0 |
38,465 |
| Cooke Julie | Chief Human Resources Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
1,741 |
0 |
28,599 |
| Delaet Ingrid | Chief Regulatory Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
801 |
0 |
5,531 |
| Gano Kyle | Chief Executive Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,927 |
0 |
143,334 |
| GORMAN KEVIN CHARLES | Director |
Jan 31 '26 |
Option Exercise |
0.00 |
5,142 |
0 |
519,738 |
| Lippoldt Darin | Chief Legal Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
2,373 |
0 |
49,127 |
| Onyia Jude | Chief Scientific Officer |
Jan 31 '26 |
Option Exercise |
0.00 |
238 |
0 |
16,119 |
| Gano Kyle | Chief Executive Officer |
Jan 16 '26 |
Option Exercise |
35.99 |
36,400 |
1,310,036 |
174,995 |
| Gano Kyle | Chief Executive Officer |
Jan 16 '26 |
Sale |
132.70 |
36,400 |
4,830,458 |
140,407 |
1.37%
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):